Thank you for your interest in the Kansas Veterinary Regenerative Symposium. As you may be aware, we are fortunate to have attracted some of the world’s most qualified speakers in the field of regenerative medicine. So you can understand a little more about this exciting field as well as our distinguished speakers, we will be intermittently posting selected publications (either full articles or abstracts). Our first article of note is co-authored by Dr. Dori Borjesson from the University of California, Davis.Stem cells in canine spinal cord injury show promise for regenerative therapy in a large animal model of human disease.
Stem cells in canine spinal cord injury–promise for regenerative therapy in a large animal model of human disease.
- 1Stem Cell Program, Institute for Regenerative Cures, 2921 Stockton Boulevard, CA, 95817, USA.
The use of cell transplantation for spinal cord injury is a rapidly evolving field in regenerative medicine. Numerous animal models are currently being used. However, translation to human patients is still a challenging step. Dogs are of increasing importance as a translational model for human disease since there is a greater awareness of the need to increase the quality of preclinical data. The use of dogs ultimately brings benefit to both human and veterinary medicine. In this review we analyze experimental and clinical studies using cell transplantation for canine spinal cord injury. Overall, in experimental studies, transplantation groups showed improvement over control groups. Improvements were measured at the functional, electrophysiological, histological, RNA and protein levels. Most clinical studies support beneficial effects of cell transplantation despite the fact that methodological limitations preclude definitive conclusions. However, the mechanisms of action and underlying the behavior of transplanted cells in the injured spinal cord remain unclear. Overall, we conclude here that stem cell interventions are a promising avenue for the treatment of spinal cord injury. Canines are a promising model that may help bridge the gap between translational research and human clinical trials.
Stem Cell Rev. 2015 Feb;11(1):180-93. doi: 10.1007/s12015-014-9553-9.